Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Simone Ragusa, Borja Prat-Luri, Alejandra González-Loyola, Sina Nassiri, Mario Leonardo Squadrito, Alan Guichard, Sabrina Cavin, Nikolce Gjorevski, David Barras, Giancarlo Marra, Matthias P. Lutolf, Jean Perentes, Emily Corse, Roberta Bianchi, Laureline Wetterwald, Jaeryung Kim, Guillermo Oliver, Mauro Delorenzi, Michele De Palma, Tatiana V. Petrova*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential responses of APC-mutant CRCs to chemotherapy are not well understood. We report that expression of the transcription factor prospero homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. In genetic Apc-mutant mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically silent tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it promoted further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and immunostimulatory reprogramming of Prox1-deficient tumors, destroyed tumor fibrosis, and unleashed T cell–mediated killing of cancer cells. These results pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate a therapeutic strategy for chemoresistant and desmoplastic CRCs.

Original languageEnglish (US)
Pages (from-to)1199-1216
Number of pages18
JournalJournal of Clinical Investigation
Volume130
Issue number3
DOIs
StatePublished - Mar 2 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice'. Together they form a unique fingerprint.

  • Cite this

    Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., Lutolf, M. P., Perentes, J., Corse, E., Bianchi, R., Wetterwald, L., Kim, J., Oliver, G., Delorenzi, M., De Palma, M., & Petrova, T. V. (2020). Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. Journal of Clinical Investigation, 130(3), 1199-1216. https://doi.org/10.1172/JCI129558